A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab

Real-World Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab in Italy

This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.

Inclusion criteria:

• A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period.
• Age ≥18 years at index date.
• With at least 12 months data availability prior to index date.

Exclusion criteria:

• Patients who received either evolocumab or alirocumab as their index study drug and who were dispensed the other anti-PCSK9-mAb (alirocumab and evolocumab respectively) before the identification period.